IO Frontiers World 2019

Supply chain & Logistics for Advanced Therapies


The cell and gene therapy sectors are maturing with more and more products nearing the market, however the challenges of regulatory approval and creating a commercially viable product are far from being solved.

One of the main barriers to commercial viability is the supply chain, which contributes hugely to the overall cost of goods (COGs) and is limited by infrastructure, temperature requirements and, of course, the time frame for transportation vs. cell viability.

In this e-book we explore the impact of the supply chain on commercialisation and provide in depth insight and knowledge from the industry to prevent further failures and ensure the best levels of patient care can reach the market, including:

  • Designing a robust, flexible supply chain design
  • The impact of product formulation on storage needs and supply chain costs

Please fill in the form below to access the Ebook

As an anti-spam measure, please type the characters you see in the image (case sensitive).
  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy